Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection

Journal of General Virology

Volumn 94, Issue PART7, 2013, Pages 1647-1657

  Benfield, Camilla T O ^a   Ren, Hongwei ^a   Lucas, Stuart J ^b,d   Bahsoun, Basma ^b,c   Smith, Geoffrey L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c SABANCI UNIVERSITY   (Turkey)

^d UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; VACCINIA VIRUS PROTEIN K7; VIRULENCE FACTOR; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL CULTURE; CODON; CONTROLLED STUDY; CYTOLYSIS; FEMALE; FRAMESHIFT MUTATION; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION; INNATE IMMUNITY; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSLATION INITIATION; VACCINIA VIRUS; VIRUS GENE; VIRUS REPLICATION; WEIGHT REDUCTION;

ANIMALS; CELL LINE; DERMIS; FEMALE; HELA CELLS; HUMANS; IMMUNITY, INNATE; L CELLS (CELL LINE); LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; VACCINIA; VACCINIA VIRUS; VIRAL PROTEINS; VIRULENCE; VIRULENCE FACTORS;

MURINAE; VACCINIA VIRUS;

EID: 84879163595     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.052670-0     Document Type: Article

References (76)

1. Alcamí, A. & Smith, G. L. (1992). A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71, 153-167.
2. Alcamí, A. & Smith, G. L. (1995). Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 69, 4633-4639.
3. Alcamí, A. & Smith, G. L. (1996). A mechanism for the inhibition of fever by a virus. Proc Natl Acad Sci U S A 93, 11029-11034.
4. Antoine, G., Scheiflinger, F., Dorner, F. & Falkner, F. G. (1998). The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396.
5. Aoyagi, M., Zhai, D., Jin, C., Aleshin, A. E., Stec, B., Reed, J. C. & Liddington, R. C. (2007). Vaccinia virus N1L protein resembles a B cell lymphoma-2 (Bcl-2) family protein. Protein Sci 16, 118-124.
6. Assarsson, E., Greenbaum, J. A., Sundström, M., Schaffer, L., Hammond, J. A., Pasquetto, V., Oseroff, C., Hendrickson, R. C., Lefkowitz, E. J. & other authors (2008). Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci U S A 105, 2140-2145.
7. Bahar, M. W., Kenyon, J. C., Putz, M. M., Abrescia, N. G., Pease, J. E., Wise, E. L., Stuart, D. I., Smith, G. L. & Grimes, J. M. (2008). Structure and function of A41, a vaccinia virus chemokine binding protein. PLoS Pathog 4, e5.
8. Bahar, M. W., Graham, S. C., Chen, R. A., Cooray, S., Smith, G. L., Stuart, D. I. & Grimes, J. M. (2011). How vaccinia virus has evolved to subvert the host immune response. J Struct Biol 175, 127-134.
9. Bartlett, N., Symons, J. A., Tscharke, D. C. & Smith, G. L. (2002). The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. J Gen Virol 83, 1965-1976.
10. Benfield, C. T., Mansur, D. S., McCoy, L. E., Ferguson, B. J., Bahar, M. W., Oldring, A. P., Grimes, J. M., Stuart, D. I., Graham, S. C. & Smith, G. L. (2011). Mapping the IkappaB kinase beta (IKKbeta)-binding interface of the B14 protein, a vaccinia virus inhibitor of IKKbetamediated activation of nuclear factor kappaB. J Biol Chem 286, 20727-20735.
11. Bennink, J. R., Yewdell, J. W., Smith, G. L. & Moss, B. (1986). Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol 57, 786-791.
12. Blanchard, T. J., Alcamí, A., Andrea, P. & Smith, G. L. (1998). Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 79, 1159-1167.
13. Bukowski, J. F., Woda, B. A., Habu, S., Okumura, K. & Welsh, R. M. (1983). Natural killer cell depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol 131, 1531-1538.
14. Chen, R. A., Jacobs, N. & Smith, G. L. (2006). Vaccinia virus strain Western Reserve protein B14 is an intracellular virulence factor. J Gen Virol 87, 1451-1458.
15. Chen, R. A., Ryzhakov, G., Cooray, S., Randow, F. & Smith, G. L. (2008). Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog 4, e22.
16. Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C. & Smith, G. L. (2006). Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 87, 29-38.
17. Colamonici, O. R., Domanski, P., Sweitzer, S. M., Larner, A. & Buller, R. M. (1995). Vaccinia virus B18R gene encodes a type I interferonbinding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 270, 15974-15978.
18. Cooray, S., Bahar, M. W., Abrescia, N. G., McVey, C. E., Bartlett, N. W., Chen, R. A., Stuart, D. I., Grimes, J. M. & Smith, G. L. (2007). Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein. J Gen Virol 88, 1656-1666.
19. Cottingham, M. G., Andersen, R. F., Spencer, A. J., Saurya, S., Furze, J., Hill, A. V. & Gilbert, S. C. (2008). Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One 3, e1638.
20. Doceul, V., Hollinshead, M., van der Linden, L. & Smith, G. L. (2010). Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science 327, 873-876.
21. Fahy, A. S., Clark, R. H., Glyde, E. F. & Smith, G. L. (2008). Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. J Gen Virol 89, 2377-2387.
22. Falivene, J., Del Mé dico Zajac, M. P., Pascutti, M. F., Rodríguez, A. M., Maeto, C., Perdiguero, B., Gó mez, C. E., Esteban, M., Calamante, G. & Gherardi, M. M. (2012). Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS ONE 7, e32220.
23. Falkner, F. G. & Moss, B. (1990). Transient dominant selection of recombinant vaccinia viruses. J Virol 64, 3108-3111.
24. Fenner, F., Anderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. (1988). Smallpox and its Eradication. Geneva: World Health Organization.
25. García-Arriaza, J., Nájera, J. L., Gó mez, C. E., Tewabe, N., Sorzano, C. O., Calandra, T., Roger, T. & Esteban, M. (2011). A candidate HIV/ AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS ONE 6, e24244.
26. Gómez, C. E., Perdiguero, B., Nájera, J. L., Sorzano, C. O., Jimé nez, V., González-Sanz, R. & Esteban, M. (2012). Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 86, 5026-5038.
27. González, J. M. & Esteban, M. (2010). A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J 7, 59.
28. Goulding, J., Bogue, R., Tahiliani, V., Croft, M. & Salek-Ardakani, S. (2012). CD8 T cells are essential for recovery from a respiratory vaccinia virus infection. J Immunol 189, 2432-2440.
29. Graham, S. C., Bahar, M. W., Cooray, S., Chen, R. A., Whalen, D. M., Abrescia, N. G., Alderton, D., Owens, R. J., Stuart, D. I. & other authors (2008). Vaccinia virus proteins A52 and B14 share a Bcl-2- like fold but have evolved to inhibit NF-kappaB rather than apoptosis. PLoS Pathog 4, e1000128.
30. Harte, M. T., Haga, I. R., Maloney, G., Gray, P., Reading, P. C., Bartlett, N. W., Smith, G. L., Bowie, A. & O'Neill, L. A. (2003). The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 197, 343-351.
31. Hughes, S. J., Johnston, L. H., de Carlos, A. & Smith, G. L. (1991). Vaccinia virus encodes an active thymidylate kinase that complements a cdc8 mutant of Saccharomyces cerevisiae. J Biol Chem 266, 20103-20109.
32. Jacobs, N., Chen, R. A., Gubser, C., Najarro, P. & Smith, G. L. (2006). Intradermal immune response after infection with Vaccinia virus. J Gen Virol 87, 1157-1161.
33. Jacobs, N., Bartlett, N. W., Clark, R. H. & Smith, G. L. (2008). Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection. J Gen Virol 89, 2877-2881.
34. Kalverda, A. P., Thompson, G. S., Vogel, A., Schröder, M., Bowie, A. G., Khan, A. R. & Homans, S. W. (2009). Poxvirus K7 protein adopts a Bcl-2 fold: biochemical mapping of its interactions with human DEAD box RNA helicase DDX3. J Mol Biol 385, 843-853.
35. Kotwal, G. J., Hügin, A. W. & Moss, B. (1989). Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein. Virology 171, 579-587.
36. Kvansakul, M., Yang, H., Fairlie, W. D., Czabotar, P. E., Fischer, S. F., Perugini, M. A., Huang, D. C. & Colman, P. M. (2008). Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ 15, 1564-1571.
37. Lane, J. M., Ruben, F. L., Neff, J. M. & Millar, J. D. (1969). Complications of smallpox vaccination, 1968. N Engl J Med 281, 1201-1208.
38. Lathe, R., Kieny, M. P., Gerlinger, P., Clertant, P., Guizani, I., Cuzin, F. & Chambon, P. (1987). Tumour prevention and rejection with recombinant vaccinia. Nature 326, 878-880.
39. Mackett, M., Smith, G. L. & Moss, B. (1982). Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 79, 7415-7419.
40. Maluquer de Motes, C., Cooray, S., Ren, H., Almeida, G. M., McGourty, K., Bahar, M. W., Stuart, D. I., Grimes, J. M., Graham, S. C. & Smith, G. L. (2011). Inhibition of apoptosis and NF-kB activation by vaccinia protein N1 occur via distinct binding surfaces and make different contributions to virulence. PLoS Pathog 7, e1002430.
41. Martinez, J., Huang, X. & Yang, Y. (2010). Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog 6, e1000811.
42. Moore, J. B. & Smith, G. L. (1992). Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. EMBO J 11, 1973-1980.
43. Moss, B. (2007). Poxviridae: the viruses and their replicaton. In Fields Virology, 5th edn, pp. 2905-2946. Edited by D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman & S. E. Straus. Philadelphia: Lippincott Williams & Wilkins.
44. Mossman, K., Upton, C., Buller, R. M. & McFadden, G. (1995). Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 208, 762-769.
45. Mulhern, O. & Bowie, A. G. (2010). Unexpected roles for DEAD-box protein 3 in viral RNA sensing pathways. Eur J Immunol 40, 933-935.
46. Ng, A., Tscharke, D. C., Reading, P. C. & Smith, G. L. (2001). The vaccinia virus A41L protein is a soluble 30 kDa glycoprotein that affects virus virulence. J Gen Virol 82, 2095-2105.
47. Oda, S., Schröder, M. & Khan, A. R. (2009). Structural basis for targeting of human RNA helicase DDX3 by poxvirus protein K7. Structure 17, 1528-1537.
48. Osman, M., Kubo, T., Gill, J., Neipel, F., Becker, M., Smith, G., Weiss, R., Gazzard, B., Boshoff, C. & Gotch, F. (1999). Identification of human herpesvirus 8-specific cytotoxic T-cell responses. J Virol 73, 6136-6140.
49. Panicali, D. & Paoletti, E. (1982). Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 79, 4927-4931.
50. Panicali, D., Davis, S. W., Weinberg, R. L. & Paoletti, E. (1983). Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant Vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A 80, 5364-5368.
51. Parker, A. K., Parker, S., Yokoyama, W. M., Corbett, J. A. & Buller, R. M. (2007). Induction of natural killer cell responses by ectromelia virus controls infection. J Virol 81, 4070-4079.
52. Parkinson, J. E. & Smith, G. L. (1994). Vaccinia virus gene A36R encodes a M(r) 43-50 K protein on the surface of extracellular enveloped virus. Virology 204, 376-390.
53. Reading, P. C. & Smith, G. L. (2003a). A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J Gen Virol 84, 1973-1983.
54. Reading, P. C. & Smith, G. L. (2003b). Vaccinia virus interleukin-18- binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J Virol 77, 9960-9968.
55. Reading, P. C., Moore, J. B. & Smith, G. L. (2003a). Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J Exp Med 197, 1269-1278.
56. Reading, P. C., Symons, J. A. & Smith, G. L. (2003b). A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection. J Immunol 170, 1435-1442.
57. Schröder, M., Baran, M. & Bowie, A. G. (2008). Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 27, 2147-2157.
58. Seet, B. T., Johnston, J. B., Brunetti, C. R., Barrett, J. W., Everett, H., Cameron, C., Sypula, J., Nazarian, S. H., Lucas, A. & McFadden, G. (2003). Poxviruses and immune evasion. Annu Rev Immunol 21, 377-423.
59. Smith, G. L., Mackett, M. & Moss, B. (1983a). Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302, 490-495.
60. Smith, G. L., Murphy, B. R. & Moss, B. (1983b). Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A 80, 7155-7159.
61. Smith, G. L., Symons, J. A., Khanna, A., Vanderplasschen, A. & Alcamí, A. (1997). Vaccinia virus immune evasion. Immunol Rev 159, 137-154.
62. Smith, V. P., Bryant, N. A. & Alcamí, A. (2000). Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J Gen Virol 81, 1223-1230.
63. Soulat, D., Bü rckstü mmer, T., Westermayer, S., Goncalves, A., Bauch, A., Stefanovic, A., Hantschel, O., Bennett, K. L., Decker, T. & Superti-Furga, G. (2008). The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO J 27, 2135-2146.
64. Spriggs, M. K., Hruby, D. E., Maliszewski, C. R., Pickup, D. J., Sims, J. E., Buller, R.M. & VanSlyke, J. (1992). Vaccinia and cowpox viruses encode a novel secreted interleukin-1-binding protein. Cell 71, 145-152.
65. Stack, J., Haga, I. R., Schröder, M., Bartlett, N. W., Maloney, G., Reading, P. C., Fitzgerald, K. A., Smith, G. L. & Bowie, A. G. (2005). Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 201, 1007-1018.
66. Staib, C., Kisling, S., Erfle, V. & Sutter, G. (2005). Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 86, 1997-2006.
67. Sumner, R. P., Ren, H. & Smith, G. L. (2013). Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J Gen Virol 94, 1121-1126.
68. Sutter, G. & Staib, C. (2003). Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3, 263-271.
69. Symons, J. A., Alcamí, A. & Smith, G. L. (1995). Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81, 551-560.
70. Tscharke, D. C. & Smith, G. L. (1999). A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 80, 2751-2755.
71. Tscharke, D. C., Reading, P. C. & Smith, G. L. (2002). Dermal infection with Vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 83, 1977-1986.
72. Unterholzner, L., Sumner, R. P., Baran, M., Ren, H., Mansur, D. S., Bourke, N. M., Randow, F., Smith, G. L. & Bowie, A. G. (2011). Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 7, e1002247.
73. Walsh, S. R. & Dolin, R. (2011). Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines 10, 1221-1240.
74. Williamson, J. D., Reith, R. W., Jeffrey, L. J., Arrand, J. R. & Mackett, M. (1990). Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 71, 2761-2767.
75. Xu, R., Johnson, A. J., Liggitt, D. & Bevan, M. J. (2004). Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 172, 6265-6271.
76. Yang, Z., Bruno, D. P., Martens, C. A., Porcella, S. F. & Moss, B. (2010). Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A 107, 11513-11518.